BMAC (Bone Marrow Aspirate Concentrate) injection is an advanced regenerative therapy offered at the London Cartilage Clinic. This cutting-edge treatment utilizes the healing properties of the patient's own bone marrow cells to treat various knee conditions, including osteoarthritis, sports injuries, and cartilage damage. BMAC injections are minimally invasive and provide a promising alternative to more extensive knee surgeries.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertise
BMAC therapy uses your own bone marrow aspirate, concentrated to increase the cellular and growth-factor components delivered to the affected area.
This approach aims to reduce inflammation, improve function, and support tissue repair while avoiding more invasive surgery in selected cases.
BMAC is often selected for patients seeking a biologic, minimally invasive option for degenerative or sports-related knee conditions.
At London Cartilage Clinic, BMAC protocols are specialist-led and individualised to your pathology, imaging findings, and recovery goals.
You may have more options than you think
At London Cartilage Clinic we follow a structured clinical framework across four areas of treatment. Before recommending a single procedure, we assess which combination of approaches gives you the best outcome.
Protect what you have. Slow degeneration and manage symptoms.
Fix specific damage. Torn tissue, unstable joints, structural problems.
Rebuild lost tissue. Biological treatments that stimulate new growth.
When other options are exhausted. Joint replacement as a last resort.
This treatment can be applied across multiple joints. Select yours to see the full range of options we offer, organised by clinical approach.
Explore All Treatment Options
BMAC injections are effective in treating a range of knee conditions, including osteoarthritis, sports-related injuries, and cartilage degeneration.
Patients typically experience minimal discomfort during the BMAC injection procedure. Local anesthesia is used to ensure patient comfort.
Results can vary, but many patients report improvement in pain and mobility within a few weeks of the treatment. The full benefits of the injection may continue to develop over several months.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
For active patients with cartilage defects, OATS and microfracture produce similar results at two years, but ten-year data favour OATS decisively: 14% treatment failure against 38% for microfracture—a gap reflecting tissue type, as fibrocartilage wears under athletic load whilst genuine hyaline cartilage endures.
Since its introduction in 2013, ChondroFiller has recorded zero serious adverse device effects across more than 19,000 treated cases, with a device complaint rate of 0.06%.
High-grade cartilage lesions on MRI (ICRS Grade 3–4) appear in 5–10% of symptom-free adults; cartilage grade and symptoms do not correlate, and severity alone does not determine whether surgery is required.
